Miodrag Vrbic, Maja Jovanovic, Lidija Popovic-Dragonjic, Aleksandar Rankovic, Marina Djordjevic-Spasic

DOI Number
First page
Last page


The number of CD4 lymphocytes defines the evolutional stage of HIV-infection and is the most important for a reliable estimation of the individual risk of developing AIDS. However, it is difficult to predict the degree of immune reconstitution during antiretroviral therapy, as it varies significantly from one person to another. Further investigations to better understand the limitations of immunological success are necessary to improve the response to treatment and regimen durability. The current study includes HIV-infected patients in Southeastern Serbia with achieved virologic suppression of HIV infection. The CD4 count was determined by flow cytometry, and was correlated with the duration of treatment, initial number of CD4 cells, type of antiretroviral therapy, mode of transmission of infection, age and gender of examinees. The resulting arithmetic mean and standard deviation of CD4 number was 473±259 cells/µl (range, 1130 cells/µl). There was no statistically significant correlation between the values of CD4 count and length of treatment, stage of the infection at which the therapy was started, treatment profile, method of infection, age or gender. The obtained results are comparable with the existing studies that follow immunological response to antiretroviral therapy and primarily point out the issue of substantial individual response variability, which has not yet been fully elucidated.


HIV, immune response, cART

Full Text:



Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: Monitoring the response to ART and the diagnosis of treatment. World Health Organization 2013; 7:133-137.

Migueles SA, Connors M. Success and failure of the cellular immune response against HIV-1. Nature Immunology 2015; 16:563-570.

EACS Guidelines Version 8.1 ostober 2016 /EACS Guidelines 8.1 PART II 11.

Gatell JM, Rockstroh JK, Furrer H, et al. EACS Guidelines Version 8.2 january 2017 PART II 12

Mocroft A, Phillips AN, Gatell J, et al. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007; 370:407-413.

Kaufman GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to < 500cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis 2005; 41:362-372.

Moing V, Thiebaut R, Chene G, et al. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently < 500 copies/mL during treatment with antiretroviral drugs. HIV Medicine 2007; 8:156–163.

Bishop JD, DeShields S, Cunningham T, et al. CD4 Count Recovery After Initiation of Antiretroviral Therapy in Patients Infected With Human Immunodeficiency Virus. American Journal of the Medical Science 2016; 352:239-244.

Le Moing V, Thiebaut R, Chene G, et al. Predictors of log-term increase in CD4+ cell counts in HIV-infected patients receiving a protease inhibitor-containing antiretroviral regimen. J Infect Dis 2002; 185:471-480.

Antinori A , Coenen T, Costagiola D, et al. Late presentation of HIV infection: a consensus definition. HIV Med 2011; 12:6164.

Borghi V, Girardi E, Bellelli S, et al. Late presenters in an HIV surveillance system in Italy during the period 1992-2006. J Acquir Immune Defic Syndr 2008; 49:282-286.

Hoffmann C. Incidence and risk factors of late HIV diagnosis. In: Hoffmann C, Rockstroh JK, editors. HIV 2015/2016. Medizin Fokus Werlag, Hamburg 2015; 171-172.

Hoffmann C. Discordinant response. In: Hoffmann C, Rockstroh JK, editors. HIV 2015/2016. Medizin Fokus Werlag, Hamburg 2015; 148-150.

Kelley CF, Kitchen CM, Hunt PW, et al. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009; 48:787-794.

Gazzola L, Tincati C,Monforte AA, Marchetti G. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis 2009; 48:328-337.

Zoufaly A, der Heiden M, Kollan C, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis 2011; 203:364-371.

Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. US Department of Healt and Human Services 2015-04-08.

Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subset on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis 2009; 48:350-361.

Lok JJ, Bosch RJ, Benson CA, et al. Long=term increase in CD4+ T-cell count during combination antiretroviral therapy for HIV-1 infection. AIDS 2010; 24:1867-1876.

Viard JP, Macroft A, Chiesi A, et al. Influenece of age on CD4 cell recovery in HIV-infected patients reciving HAART: evidence from EuroSIDA study. J Infect Dis 2001; 183:1290-1294.

Graber S, Kausignian I, Sobel A. at al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Reults from the French Hospital Database on HIV. AIDS 2004; 18:2029-2038.

Torti C, d’Armino-Monforte A, Pozniak AL, et al. Long-term CD4+ T-cell countevolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infect Dis 2011:11-23.

Castilho JL, Melekhin VV, Sterlin TR. Sex Differences in HIV Outcomes in the Highly Active Antiretroviral Therapy Era: A Systematic Review. Res Hum Retroviruses 2014; 30:446-456.



  • There are currently no refbacks.

ISSN 0354-2017 (Print)

ISSN 2406-0526  (Online)